New study tests heart failure drugs in patients with kidney problems
NCT ID NCT05279742
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study looks at how two drugs, Sacubitril/Valsartan (Entresto) and MANP, affect people with a type of heart failure called HFpEF, which also involves chronic kidney disease or shortness of breath during exercise. Researchers will measure changes in body fluids and certain chemicals to understand how these drugs work. The study involves 60 adults and aims to gather information rather than provide direct treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.